0
0
Read Time:11 Minute, 2 Second
The DNA Sequencing Market will grow at a CAGR of 11.8% during the forecast period to reach $21.30 billion by 2031, says Meticulous Research®. DNA sequencing is a method used to determine the nucleotide sequence of DNA. By sequencing nucleotides, researchers gain the most detailed understanding of a gene or genome. This sequence serves as a blueprint, providing essential information for building an organism, and is crucial for a complete understanding of genetic function and evolution.
The growth of the DNA sequencing market is driven by factors such as the declining costs of DNA sequencing, the growing need for the early diagnosis of diseases such as cancer & genetic disorders, the growing utilization of DNA sequencing in precision medicine, increasing R&D expenditures, improvements in regulatory & reimbursement scenarios for DNA sequencing, rising healthcare expenditures, technological advancements in sequencing tools, and government initiatives promoting the use of sequencing in clinical & research applications. However, the low chances of identifying positive, actionable mutations for precision medicine and the ethical & legal issues related to DNA sequencing-based diagnosis restrain the growth of this market.
Furthermore, the increasing applications of DNA sequencing, government support for large-scale genomic sequencing projects, the rising awareness & adoption of targeted therapies, and emerging economies are expected to generate growth opportunities for the players operating in this market. However, uncertainties in the regulatory landscape, the limited expertise & sequencing capabilities of small & medium-sized laboratories, the lack of sequencing professionals in developing countries, and the high capital investments required for NGS setups are major challenges impacting market growth.
Additionally, emerging DNA sequencing companies’ focus on improving technologies and reducing costs and key market players’ emphasis on portable and real-time sequencing technologies are prominent trends in the DNA sequencing market.
Here are the top 10 companies operating in the DNA Sequencing Market
Incorporated in 1998 and headquartered in California, the U.S., Illumina provides sequencing and array-based solutions for genomic and genetic analysis. The company operates through two reportable segments: Core Illumina and GRAIL. The company provides a wide range of DNA sequencing solutions used for clinical and research applications.
Illumina provides its products to government laboratories, genomic research centers, academic institutions, hospitals, commercial molecular diagnostic laboratories, and pharmaceutical and consumer genomics companies. The company has manufacturing sites and laboratories in the U.S., Singapore, and the U.K. It distributes its products directly and through distributors to its customers in Australia, New Zealand, Germany, China, France, India, Japan, the Netherlands, and the U.K., among others.
Some of its subsidiaries operating in the DNA sequencing market are Illumina GmbH (Germany), Illumina Australia Pty. Ltd. (Australia), Illumina U.K., Ltd. (U.K.), Illumina Italy S.r.l. (Italy), Illumina Netherlands B.V. (Netherlands), and Illumina K.K. Japan (Japan).
Thermo Fisher Scientific Inc. (U.S.)
Founded in 1956 and headquartered in Massachusetts, the U.S., Thermo Fisher offers products and services in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, government, and academic sectors. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
The company provides DNA sequencing solutions through its Life Sciences Solutions segment. The Life Sciences Solutions segment provides reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. These products and services are used by customers in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, and academic markets. Life Sciences Solutions includes three primary businesses: Biosciences, Genetic Sciences, and Bioproduction.
Thermo Fisher has a geographical presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa through its subsidiaries, R&D sites, and distribution network. As of December 2023, the company had a headcount of 122,000 employees, of which 61,000 were employed in the Americas, 20,000 in Asia-Pacific, and 41,000 in Europe and the Middle East & Africa.
Some of its major subsidiaries are Thermo Fisher Germany B.V (Netherlands), Thermo Fisher Scientific Inc. (Mexico) LLC (U.S.), Thermo Fisher Scientific Inc. Oy (Finland), Thermo Fisher Scientific Inc. FLC LLC (U.S.), and Thermo Fisher Scientific Inc. Australia Pty Ltd (Australia).
Agilent Technologies, Inc. (U.S.)
Founded in 1999 and headquartered in California, the U.S., Agilent Technologies provides application-focused solutions to the life sciences, diagnostics, and applied chemical markets. The company operates through three business segments: Life Sciences and Applied Markets, Agilent Cross Lab, and Diagnostics and Genomics. The Diagnostics and Genomics segment offers DNA sequencing products. The Diagnostics and Genomics segment includes genomics, nucleic acid contract manufacturing and research & development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. This segment consists of six areas of activity providing active pharmaceutical ingredients for oligo-based therapeutics and solutions that include reagents, instruments, software, and consumables.
Agilent has a geographical presence in countries including Brazil, Canada, Mexico, Austria, Belgium, Finland, Germany, Ireland, Israel, Netherlands, Spain, Japan, Korea, India, and China among others. Through its subsidiaries and distribution network, the company serves customers in over 110 countries. The company has R&D and manufacturing sites in California, Colorado, Delaware, Massachusetts, Texas, Vermont, and Washington in the U.S., Australia, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore, and the U.K.
Some of the company’s subsidiaries are Agilent Technologies Canada Inc. (Canada), Agilent Technologies U.K. Limited (U.K.), Agilent Technologies Deutschland GmbH (Germany), Agilent Technologies Company Limited (China), Agilent Technologies Japan, Ltd (Japan), Agilent Technologies Brazil Ltda. (Brazil), and Agilent Technologies France SAS (France).
QIAGEN N.V. (Netherlands)
Founded in 1984 and headquartered in Venlo, the Netherlands, QIAGEN N.V. provides sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research. The company offers its products through only one reportable segment and provides them in two major markets: Molecular Diagnostics and Life Sciences.
The company offers its DNA sequencing solutions through the Genomics/NGS segment. Qiagen’s product offerings include diagnostic solutions, PCR products, genomic or NGS products, consumables, and instruments for sample technologies. Moreover, the company offers more than 500 core products consisting of instruments, kits, bioinformatics solutions, and a wide range of NGS services, such as RNA sequencing services, DNA sequencing services, whole genome amplification services, and RNA isolation services.
The company markets products in more than 130 countries across the globe. It has facilities in the U.S., China, Germany, Poland, the Philippines, Denmark, Romania, Spain, the U.K., and other countries. Furthermore, the company’s sales are handled by distributors and subsidiaries. Some of the company’s key subsidiaries are QiagenAB (Sweden), Qiagen AG (Sweden), Qiagen GmbH (Germany), QIAGEN LLC (U.S.), QIAGEN China (Shanghai) Co. Ltd. (China), QIAGEN Inc. (Canada), QIAGEN K.K. (Japan), and QIAGEN S.r.l. (Italy).
Founded in 1984 and headquartered in Washington, D.C., the U.S., Danaher Corporation designs, manufactures, and markets medical, professional, industrial, and commercial products and services for various end users. The company is comprised of more than 15 operating companies and operates through four reportable business segments: Life Sciences, Biotechnology, Diagnostics, and Environmental and Applied Solutions.
The Life Sciences segment offers products for the DNA sequencing market. The company has research and development, manufacturing, sales, distribution, service, and administrative facilities in more than 60 countries across the globe. Danaher Corporation sells its products through direct sales personnel and independent distributors.
Some of Danaher Corporation’s subsidiaries offering DNA sequencing solutions are Beckman Coulter, Inc. (U.S.) and Integrated DNA Technologies, Inc. (U.S.). Some of its other subsidiaries are Beckman Coulter Biomedical Ltd. (Ireland), Beckman Coulter Commercial Enterprise Co., Ltd. (China), Beckman Coulter France S.A.S. (France), Beckman Coulter GmbH (Germany), Beckman Coulter United Kingdom (U.K.), Beckman Coulter India Pvt Ltd (India), Beckman Coulter Australia Pty. Ltd. (Australia), Beckman Coulter Korea Ltd. (South Korea).
Meticulous Research in its latest publication on DNA Sequencing Market has predicted the growth of 11.8% during the forecast year 2024-2031.
F. Hoffmann-La Roche Ltd (Switzerland)
Founded in 1896 and headquartered in Basel, Switzerland, Roche is a healthcare company that develops, manufactures, and markets a wide range of healthcare solutions. The company operates through two reportable divisions, namely, Pharmaceuticals and Diagnostics, of which the Diagnostics division operates in the DNA sequencing market.
The Diagnostics division is engaged in developing a wide range of diagnostic products and solutions, such as in vitro diagnostics, molecular diagnostics, clinical chemistry and immunoassays, point-of-care testing, tissue diagnostics, patient self-testing, next-generation sequencing, laboratory automation and IT, and decision-support solutions.
Roche has a geographical presence across the U.S., Germany, Switzerland, Japan, China, India, New Zealand, Australia, Latin America, and Africa. Furthermore, the company has 23 manufacturing sites and 29 research and development sites worldwide. Some of its subsidiaries are Roche Diagnostics (U.S.), Roche Diagnostics GmbH (Germany), Roche Diagnostics France SAS (France), Roche Diagnostics S.p.A. (Italy), Roche Diagnostics International AG (Switzerland), Roche Diagnostics Limited (U.K.), Roche Diagnostics (Shanghai) Ltd. (China), and Roche Diagnostics K.K (Japan).
Founded in 2023 and headquartered in Massachusetts, the U.S., Revvity offers products, solutions, and services for the life sciences and diagnostics markets. It operates through two reportable business segments: Life Sciences and Diagnostics. In August 2022, the company completed the divestiture of its Applied, Food, and Enterprise Services businesses to private equity firm New Mountain Capital from PerkinElmer, Inc. (U.S.).
The company has a network of sales and marketing channels and service personnel in over 40 countries and sells its products and services in over 160 countries.
Some of its subsidiaries are Revvity Global Diagnostics, Inc (U.S). Revvity Biomed (Shanghai) Co., Ltd., Revvity SAS (France), Revvity Germany Diagnostics GmbH (Germany), Revvity Healthcare (India) Pvt Ltd., Revvity Japan Co. Ltd., Revvity Korea, Ltd., Nexcelom Bioscience Ltd. (U.K.).
Pacific Biosciences of California, Inc. (U.S.)
Incorporated in 2004 and headquartered in California, the U.S., Pacific Biosciences of California is a life science technology company that designs, develops, and manufactures advancing sequencing solutions that help researchers and scientists solve genetically complex problems. The company focuses on two core technologies: HiFi long-read sequencing technology and short-read sequencing by binding (SBB) technology. Pacific Biosciences’ products address solutions to various applications, including plant and animal sciences, human germline sequencing, oncology, infectious disease and microbiology, and other emerging applications.
Pacific Biosciences operates through a single business segment and provides its products to various end users such as government and academic research institutions, service laboratories and commercial testing, genome centers, hospitals and clinical research institutions, public health labs, contract research organizations (CROs), and agricultural and pharmaceutical companies.
The company has a direct presence across the U.K. in Europe, China, Japan, South Korea, Singapore, Asia-Pacific, and the Middle East & Africa.
Founded in 2016 and headquartered in Shenzhen, China, MGI manufactures solutions for clinical high-throughput gene sequencing and other products, such as multi-omics platforms, including genetic sequencing, medical imaging, and laboratory automation.
MGI provides instruments for agriculture, precision medicine, healthcare, and other relevant industries. The company mainly focuses on R&D, production, and sales of DNA sequencing instruments, reagents, and related products in the global market.
As of December 2022, MGI operates in more than 90 countries and regions, serving more than 2,000 customers. MGI has branches in different countries, including the U.S., Japan, Hong Kong, China, UAE, and Latvia. The company has established scientific research and production bases, global training centers, and service networks in several countries and regions around the world.
As of September 30, 2023, MGI had a headcount of more than 2,900 employees, 36% of which are R&D personnel. MGI was founded as a subsidiary of BGI Group. Later, the company was spun off in September 2022 and publicly traded on the Shanghai Stock Exchange.
Oxford Nanopore Technologies Plc. (U.K.)
Founded in 2005 and headquartered in England, the U.K., Oxford Nanopore Technologies Plc. manufactures devices that sequence DNA/RNA directly. The company’s principal activities are to research, develop, manufacture, and commercialize a nanopore-based sequencing platform that allows real-time analysis of DNA or RNA.
Oxford Nanopore’s offerings enable customers to perform scientific/biomedical research in multiple application areas, including environmental analysis, cancer research, human genetics, pathogens/antimicrobial resistance, viral outbreak surveillance, microbiome analysis, and crop science. The company operates its business through two reporting segments, namely, Life Science Research Tools (LSRT) and COVID testing revenue. The Life Science Research Tools business segment offers DNA sequencing products to universities, commercial laboratories, and industrial or government research laboratories and provides sequencing to scientists. The company operates its businesses in more than 120 countries.
Authoritative Research on the DNA Sequencing Market – Global Opportunity Analysis and Industry Forecast (2024-2031)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
